Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study.
OBJECTIVE
To examine efficacy and tolerability of topiramate as an adjunctive treatment for overweight refractory bipolar patients.


METHODS
Patients (n=30) with Bipolar I or II, were provided with an open label treatment with topiramate as an add-on therapy. All patients deemed refractory to at least one mood stabilizer, were overweight, and were treated with topiramate as an adjuvant to existing medication for at least 12 weeks. The primary effectiveness measure was the Clinical Global Impression Scale (CGI). Other scales included the Young's Mania Rating Scale (YMRS), and the Hamilton Depression scale (HAMD21). Measures prior to adding topiramate were compared to those repeated at 4, 8 and 12 weeks. Tolerance, and weight changes were monitored.


RESULTS
There was significant reduction in both depressive and manic symptoms with adjunctive treatment. The mean BMI at 12 weeks of topiramate treatment dropped by 2 points (p<0.0001).


CONCLUSIONS
Topiramate is an effective adjunctive treatment in bipolar refractory patients and the significant weight reduction effects may result in important medical risk reductions, and make topiramate attractive for some obese bipolar patients.
Gabriel
A
A
University of Calgary, Calgary, Alberta, Canada. gabriel@ucalgary.ca
D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder; D004351:Drug Resistance; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009765:Obesity; D011569:Psychiatric Status Rating Scales; D000077236:Topiramate; D016896:Treatment Outcome; D015431:Weight Loss
D019440:Anti-Obesity Agents; D000077236:Topiramate; D005632:Fructose